编者按：2024年第115届美国癌症研究协会（AACR）年会将于4月5日~10日在美国圣地亚哥举行，今年大会的主题是“激励科学•推动进步•革新诊疗（Inspiring Science•Fueling Progress•Revolutionizing Care）”。本文整理出大会已公开的消化肿瘤领域中国讲者的最新研究，以飨读者。

Clinical Trials Plenary Session-新型免疫检查点抑制剂组合

CT006-Cadonilimab联合化疗对比化疗作为不可切除的局部晚期或转移性胃或胃食管交界处（G/GEJ）腺癌的一线治疗（COMPASSION-15）：一项随机、双盲、Ⅲ期试验

CT006 - Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (COMPASSION-15): A randomized, double-blind, phase 3 trial

教育专场-癌症发展

单细胞谱系追踪揭示癌前结直肠病变的起源和克隆进化

Single-cell lineage tracing reveals the origin and clonal evolution of precancerous colorectal lesions

时间：2024年4月6日，下午3:30-下午3:50

Late-Breaking Research：生物信息学、计算生物学、系统生物学和融合科学1

【摘要号：LB003/3】全面多组学分析揭示NFE2L2/KEAP1突变是放化疗期间食管鳞状细胞癌治疗耐药性的关键驱动因素

LB003/3 - Comprehensive multi-omics analysis unveils NFE2L2/KEAP1 mutations as key drivers of treatment resistance in esophageal squamous cell carcinoma during chemoradiotherapy

Late-Breaking Research：免疫学1

【摘要号：LB083/19】近红外光触发的肿瘤焦亡增强了食管癌的PD-1免疫治疗

LB083 / 19 - Near-infrared light-triggered tumor pyroptosis potentiates PD-1 immunotherapy in esophageal cancer

Late-Breaking Research：临床研究2

【摘要号：LB349/23】半胱氨酸限制增强结直肠癌的抗肿瘤免疫力

LB349/23 - Cysteine restriction enhances antitumor immunity in colorectal cancer

Late-Breaking Research：分子/细胞生物学和遗传学2

【摘要号：LB302/18】circIPO7将caprin-1从核糖体中解离，并通过抑制EGFR和mTOR抑制胃癌细胞增殖

LB302/18 - circIPO7 dissociates caprin-1 from ribosomes and inhibits gastric cancer cell proliferation by suppressing EGFR and mTOR

Late-Breaking Research：肿瘤生物学2

【摘要号：LB316/11】胰腺导管腺癌的内分泌胰腺改变

LB316/11 - Endocrine pancreas alteration in pancreatic ductal adenocarcinoma

Late-Breaking Research：生物信息学、计算生物学、系统生物学和融合科学1

【摘要号：LB016/16】基于空间转录组学的结直肠癌病理诊断与研究平台

LB016/16 - Spatial transcriptomics-based platform for pathological diagnosis and research of colorectal cancer

Minisymposium-药物发现2：新疗法

【摘要号：6581】DX126-262联合化疗（顺铂和5-Fu）在HER2阳性胃癌中显示出良好的抗肿瘤疗效

6581 - DX126-262 combined with chemotherapy (Cisplatin and 5-Fu) demonstrates promising antitumor efficacy in HER2-positive gastric cancer

Minisymposium -新型抗肿瘤药物1

【摘要号：1228】选择性FGFR4抑制剂Irpagratinib（ABSK011）在临床前HCC模型中与其他治疗药物具有广泛的协同和联合抗肿瘤作用

1228 - Selective FGFR4 inhibitor Irpagratinib (ABSK011) exhibits broad synergistic and combinatory anti-tumor effects with other therapeutic agents in preclinical HCC models

壁报专区-早期检测生物标志物1

【摘要号：1063/11】miRNA家族内的IsomiR相对比例（IRP）作为非侵入性结直肠癌检测的有效生物标志物

1063/11 - IsomiR relative proportion (IRP) within miRNA family as an efficient biomarker for noninvasive colorectal cancer detection

壁报专区-癌症中的巨噬细胞、中性粒细胞和NK细胞

【摘要号：162/4】脂肪酸合成抑制剂通过使巨噬细胞复极化并增强胃癌的抗肿瘤细胞毒性与免疫检查点抑制剂产生协同作用

162/4 - Fatty acid synthesis blockade synergizes with immune checkpoint blockade by repolarizing macrophages and enhancing anti-tumor cytotoxicity in gastric cancer

壁报专区-基质相互作用

【摘要号：281/12】FGFR2+癌症相关成纤维细胞对食管鳞状细胞癌癌症干细胞扩增的功能

281/12 - The function of FGFR2+ cancer-associated fibroblasts on cancer stem cell expansion of esophageal squamous cell carcinoma

壁报专区-生物信息学在癌症生物学中的应用1

【摘要号：865/9】与肝细胞癌复发相关的恶性细胞亚群的单细胞测序鉴定

865/9 - Single-cell sequencing identification of malignant cell subpopulations linked to recurrence in hepatocellular carcinoma

壁报专区-引线识别和优化

【摘要号：1819/14】七叶素调节SLC31A1和ATP7B影响铜稳态并触发结直肠癌的细胞死亡

1819/14 - Esculetin modulates SLC31A1 and ATP7B to influence copper homeostasis and trigger cell death in colorectal cancer

壁报专区-预测性生物标志物5

【摘要号：6400/12】替雷利珠单抗联合XELOX作为局部晚期胃癌和胃食管交界处腺癌的新辅助治疗：一项前瞻性II期试验

6400/12 - Tislelizumab combined with XELOX as a neoadjuvant therapy for locally advanced gastric and gastroesophageal junction adenocarcinomas: A prospective, phase II trial

壁报专区-Ⅱ期临床试验1

【摘要号：CT209/9】卡瑞利珠单抗加化疗作为可切除的局部晚期食管鳞状细胞癌（LA-ESCC）的新辅助治疗：一项单中心、随机、Ⅱ期试验

CT209/9 - Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): A single-center, randomized, phase II trial

壁报专区-新型免疫疗法和免疫调节

【摘要号：5097/19】阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的有效性和安全性：一项在中国进行的多中心、回顾性真实世界研究

5097/19 - Effectiveness and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A multicenter, retrospective real-world study in China